ClinicalTrials.gg
RecruitingNCT06765980VISIONUpdated Aug 10, 2026

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 1/2 interventional study of VV-14295 in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Kriya Therapeutics, Inc.. Recruiting at 4 sites in 4 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Kriya Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
62nd of 107
62 · median 98
Started
2025
with 19 others
Phase 1/2
17 of 131
7 open now
Primary completion
2027-12
later than 19 of 44 live
Registered
108th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 62nd largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 17 in phase 1/2, reaches primary completion later than 19 of the 44 other live ones, and was the 108th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).

03

Conditions studied

  • Geographic Atrophy Secondary to Age-related Macular Degeneration
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be between 55 to 80 years of age (inclusive), at the time of signing the form.
  • (BMI) of 19 to 34 kg/m2 (inclusive).
  • Must agree to use reliable for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding.
  • The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening.
  • Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.
  • For study eye, Normal Luminance BCVA of 55 letters or worse using the ETDRS charts (20/80 or worse) for Part 1a participants or 24 letters or better (approximately 20/320 Snellen equivalent) for Part 1b and Part 2 participants.
  • Fellow eye Normal Luminance BCVA of 5 letters or better using ETDRS charts (20/800 or better) for Part 1a participants or 24 letters or better (approximately 20/320 Snellen equivalent or better) for Part 1b and Part 2 participants. Fellow eye must have equivalent or better visual acuity than the study eye.

Exclusion criteria

Exclusion Criteria:

  • Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy secondary to a condition other than AMD; Exudative AMD diagnosis or any history of or active macular neovascularization (in study eye or fellow eye) and/or retinal angiomatous proliferation associated with AMD or any other cause; Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function; Active ocular or periocular infection or active uncontrolled intraocular inflammation within 3 months of Screening; History of vitrectomy, retinal detachment, or corneal transplant in the study eye; Active/history of uveitis.
  • Any ocular condition that prevents adequate imaging.
  • Medical, cognitive or psychiatric conditions that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
  • Hospitalization within 1 year prior to Screening that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
  • Any Screening test (e.g., ) or laboratory value (e.g., hematology) that in the opinion of the Investigator and/or Medical Monitor is and renders the participant not suitable for study participation.
  • Participant has a direct to the regimen (both oral and topical) or has a condition that significantly increases the risk of complication.
  • Active/history of within the past 5 years from Screening or any previous therapeutic radiation in the region of the study eye(s) at Screening. History of non-melanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia (CIN), and localized prostate cancer after treatment are not exclusionary.
  • Intraocular surgery (including lens replacement surgery) within 3 months prior to Screening.
  • History of laser therapy in the macular region.
  • History of intravitreal (IVT) therapy, such as IVT steroid injections, within 6 months prior to Screening.
  • COVID-19 vaccine within 90 days of Screening or plan to receive COVID-19 vaccine within 6 months of treatment.
  • Active use of systemic immunomodulatory drugs or systemic corticosteroids in the last 60 days. Topical steroids are not exclusionary.
  • Prior participation in another interventional clinical study for GA within the past 12 months from the last dosing at Screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Part 1a, low dose

    A single low dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

    Genetic: VV-14295

  • Experimental
    Part 1a, high dose

    A single high dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

    Genetic: VV-14295

  • Experimental
    Part 1b

    A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

    Genetic: VV-14295

  • Experimental
    Part 2

    A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

    Genetic: VV-14295

Interventions

  • GeneticVV-14295

    VV-14295 will be administered as a single suprachoroidal injection.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and abnormal ophthalmic findings

    Evaluate Part 1 safety of VV-14295 in foveal and non-foveal patients

    Time frame: 12 months

  2. Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal ECGs, and abnormal ophthalmic findings

    Evaluate Part 2 safety of VV-14295 in non-foveal GA patients

    Time frame: 12 months

  3. Rate of GA progression as assessed by optical coherence tomography (OCT)

    Part 2 efficacy of VV-14295

    Time frame: 12 months

Secondary outcomes

  1. Rate of GA progression as assessed by fundus autofluorescence (FAF)

    Parts 1 and 2 efficacy of VV-14295

    Time frame: 3, 6, and 12 months

  2. Rate of GA progression as assessed by OCT

    Parts 1 and 2 efficacy of VV-14295

    Time frame: 3, 6, and 12 months

  3. Visual function preservation as assessed by best-corrected visual acuity (BCVA)

    Parts 1 and 2 efficacy of VV-14295

    Time frame: 3, 6, and 12 months

  4. Visual function preservation as assessed by low luminance visual acuity (LLVA)

    Parts 1 and 2 efficacy of VV-14295

    Time frame: 3, 6, and 12 months

  5. Visual function preservation as assessed by microperimetry

    Parts 1 and 2 efficacy of VV-14295

    Time frame: 3, 6, and 12 months

  6. VV-14295 transgene product expression

    Concentrations of AAV vector-mediated transgene product in serum

    Time frame: 12 months

  7. Immune response to VV-14295

    Humoral and cellular responses to AAV2 capsid and transgene product; anti-AAV2 neutralization capacity in serum

    Time frame: 12 months

  8. Vector shedding profile of VV-14295

    Vector shedding in serum, tears, mucus, and urine

    Time frame: 12 months

  9. Safety of Everads Injector

    Frequency of device-related adverse events and serious adverse events

    Time frame: 1 day post-dose

07

Study locations

4 of 4 sites recruiting
  • Kriya Clinical Study Site
    Erie, Pennsylvania 16505, United States
    Recruiting
  • Kriya Clinical Study Site
    Ottawa, Ontario, Canada
    Recruiting
  • Kriya Clinical Study Site
    Tel Aviv, Israel
    Recruiting
  • Kriya Clinical Study Site
    Christchurch, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jan 9, 2025
StartActual
May 28, 2025
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06765980
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
May 28, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

VP, Medical Affairs
Contact
clinicaltrials@kriyatx.com
984-884-5058

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion